Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel Motovska Z; Widimsky PVasc Health Risk Manag 2009[]; 5 (1): 475-81Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid increase in the use of coronary intervention procedures. Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy in patients treated with percutaneous coronary intervention. However, there are two issues with clopidogrel: (1) clopidogrel's antiplatelet activity is delayed because the drug needs to be metabolized into its active form and (2) variability in patient response to clopidogrel has been demonstrated. To overcome these shortcomings of clopidogrel, new more potent inhibitors of P2Y12 receptors, which have a more rapid onset of action have been introduced for clinical evaluation. This article is a nonexhaustive review of the literature and concentrates on prasugrel, a third-generation, oral thienopyridine. The purpose is to summarize the current knowledge about the benefits and risks of prasugrel and to outline the most prudent strategies for the drug's clinical use.|Administration, Oral[MESH]|Angioplasty, Balloon, Coronary/*adverse effects/instrumentation[MESH]|Aspirin/therapeutic use[MESH]|Clopidogrel[MESH]|Coronary Thrombosis/etiology/*prevention & control[MESH]|Diabetes Complications/therapy[MESH]|Drug Resistance/genetics[MESH]|Drug Therapy, Combination[MESH]|Humans[MESH]|Myocardial Infarction/*therapy[MESH]|Piperazines/administration & dosage/adverse effects/*therapeutic use[MESH]|Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use[MESH]|Prasugrel Hydrochloride[MESH]|Risk Assessment[MESH]|Risk Factors[MESH]|Stents[MESH]|Thiophenes/administration & dosage/adverse effects/*therapeutic use[MESH]|Ticlopidine/analogs & derivatives/therapeutic use[MESH]|Treatment Outcome[MESH] |
